- Home
- CAPR vs EFT Comparison
CAPR vs EFT Comparison
Compare CAPR & EFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- EFT
- Stock Information
- Founded
- CAPR 2005
- EFT 2004
- Country
- CAPR United States
- EFT United States
- Employees
- CAPR N/A
- EFT N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- EFT Finance Companies
- Sector
- CAPR Health Care
- EFT Finance
- Exchange
- CAPR Nasdaq
- EFT Nasdaq
- Market Cap
- CAPR 324.6M
- EFT 304.3M
- IPO Year
- CAPR N/A
- EFT N/A
- Fundamental
- Price
- CAPR $4.66
- EFT $11.26
- Analyst Decision
- CAPR Strong Buy
- EFT
- Analyst Count
- CAPR 6
- EFT 0
- Target Price
- CAPR $23.17
- EFT N/A
- AVG Volume (30 Days)
- CAPR 1.9M
- EFT 100.8K
- Earning Date
- CAPR 11-10-2025
- EFT 01-01-0001
- Dividend Yield
- CAPR N/A
- EFT 10.63%
- EPS Growth
- CAPR N/A
- EFT N/A
- EPS
- CAPR N/A
- EFT 1.73
- Revenue
- CAPR $11,130,509.00
- EFT N/A
- Revenue This Year
- CAPR N/A
- EFT N/A
- Revenue Next Year
- CAPR $7,894.07
- EFT N/A
- P/E Ratio
- CAPR N/A
- EFT $7.62
- Revenue Growth
- CAPR N/A
- EFT N/A
- 52 Week Low
- CAPR $4.40
- EFT $11.10
- 52 Week High
- CAPR $20.75
- EFT $13.44
- Technical
- Relative Strength Index (RSI)
- CAPR 31.84
- EFT 32.57
- Support Level
- CAPR $5.52
- EFT $11.41
- Resistance Level
- CAPR $6.01
- EFT $11.58
- Average True Range (ATR)
- CAPR 0.49
- EFT 0.09
- MACD
- CAPR -0.06
- EFT -0.01
- Stochastic Oscillator
- CAPR 12.42
- EFT 23.26
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About EFT Eaton Vance Floating Rate Income Trust of Beneficial Interest
Eaton Vance Floating-rate Income Trust is a closed-end management investment company. The company's objective is to provide a high level of current income and its secondary objective is capital appreciation.